Renal Cell Carcinoma – Landscape & Forecast – Disease Landscape & Forecast
The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical), Keytruda (Merck & Co) plus Inlyta (Pfizer) or Lenvima / Kisplyx (Eisai), and Opdivo plus Cabometyx (Exelixis / Ipsen) have revolutionized the treatment of advanced and metastatic disease and are becoming stalwarts in the first-line setting. The expected approvals of triplet combinations incorporating immune checkpoint inhibitors and tyrosine kinase inhibitors will further diversify the first-line setting. During the forecast period, the anticipated entry of Orpathys (AstraZeneca) and zanzalintinib (Exelixis) will provide effective first-line options specifically for patients with non-clear-cell histologies. The adjuvant setting will experience the most growth in the renal cell carcinoma market, as a result of Keytruda’s label expansion to and rapid adoption in the treatment of early-stage disease. Meanwhile, the approval of Welireg (Merck & Co.) is reshaping the treatment of Von-Hippel Lindau (VHL)-associated tumors.
Questions answered
- How are the combinations of immune checkpoint inhibitors and tyrosine kinase inhibitors shaping the first-line treatment of advanced or metastatic renal cell carcinoma?
- What is the expected market impact of Keytruda’s label expansion in the adjuvant setting?
- Which are the most promising emerging regimens in the late-phase pipeline, and how will they shape the future of the renal cell carcinoma market?
- What are the drivers and constraints in the treatment of renal cell carcinoma, and how will the market evolve over the forecast period?
Product Description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key updates
- April 2023
- February 2023
- Q4 2022
- November 2022
- Q3 2022
- September 2022
- August 2022
- July 2022
- Market outlook
- Key findings
- Market share of drug classes for renal cell carcinoma: 2021
- Market share of drug classes for renal cell carcinoma: 2031
- Drug-treatable population share and major-market sales share in renal cell carcinoma: 2021
- Drug-treatable population share and major-market sales share in renal cell carcinoma: 2031
- Population positioning of current therapies in renal cell carcinoma
- Population positioning of emerging therapies in renal cell carcinoma
- Renal cell carcinoma SWOT analysis
- Market drivers and constraints
- What factors are driving the market for renal cell carcinoma?
- What factors are constraining the market for renal cell carcinoma?
- Major-market sales for renal cell carcinoma by drug-treatable population: 2021-2031
- Major-market sales of immune oncology therapies for renal cell carcinoma: 2021-2031
- Major-market sales of angiogenesis inhibitors for renal cell carcinoma: 2021-2031
- Segment-specific trends
- Patient-share dynamics of therapies for early-stage (stage I-III) renal cell carcinoma, United States: 2021-2031
- Patient-share dynamics of key therapies in first-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
- Patient-share dynamics of key therapies in first-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
- Patient-share dynamics of key therapies in second-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
- Patient-share dynamics of key therapies in second-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
- Patient-share dynamics of key therapies in third-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
- Patient-share dynamics of key therapies in third-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
- Patient-share dynamics of key therapies in fourth-line advanced or metastatic renal cell carcinoma, United States, 2021-2031
- Patient-share dynamics of key therapies in fourth-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Disease overview
- Progression of renal cell carcinoma
- Anatomy and histology of renal cell carcinoma
- Prognostic models for renal cell carcinoma
- International Metastatic RCC Database Consortium risk assessment system for stage IV renal cell carcinoma
- UCLA Integrated Staging System for renal cell carcinoma
- Classification of renal cell carcinoma
- Staging of renal cell carcinoma
- TNM staging system for renal cell carcinoma
- Definitions of the TNM staging system for renal cell carcinoma
- Key pathways and drug targets for renal cell carcinoma
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Diagnosed incident cases of renal cell carcinoma: 2021-2031
- Diagnosed incident cases of renal cell carcinoma by stage distribution: 2021-2031
- Recurrent incident cases of renal cell carcinoma: 2021-2031
- Renal cell carcinoma patient flow
- Drug-Treatable Cases of Renal Cell Carcinoma: 2020-2030
- Drug-treated cases of renal cell carcinoma: 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for renal cell carcinoma
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for renal cell carcinoma
- Current treatments used for renal cell carcinoma
- Market events influencing the use of key current therapies in renal cell carcinoma
- Key results from select clinical trials investigating Opdivo for the treatment of renal cell carcinoma
- Ongoing clinical development of Opdivo
- Key ongoing clinical trials of Opdivo in the treatment of renal cell carcinoma
- Expert insight: Opdivo
- Key results from select clinical trials investigating Opdivo and Yervoy combination therapy for the treatment of renal cell carcinoma
- Ongoing clinical development of Opdivo and Yervoy combination therapy
- Key ongoing clinical trials of Opdivo and Yervoy combination therapy in the treatment of renal cell carcinoma
- Expert insight: Opdivo and Yervoy combination therapy
- Key results from select clinical trials investigating Keytruda for the treatment of renal cell carcinoma
- Ongoing clinical development of Keytruda
- Key ongoing clinical trials of Keytruda in the treatment of renal cell carcinoma
- Expert insight: Keytruda
- Key results from select clinical trials investigating Bavencio for the treatment of renal cell carcinoma
- Ongoing clinical development of Bavencio
- Expert insight: Bavencio
- Key results from select clinical trials investigating Sutent for the treatment of renal cell carcinoma
- Expert insight: Sutent
- Key results from select clinical trials investigating Votrient for the treatment of renal cell carcinoma
- Expert insight: Votrient
- Advantages and disadvantages of Nexavar
- Expert insight: Nexavar
- Key results from select clinical trials investigating Inlyta for the treatment of renal cell carcinoma
- Expert insight: Inlyta
- Expert insight: Avastin
- Key results from select clinical trials investigating Cabometyx for the treatment of renal cell carcinoma
- Ongoing clinical development of Cabometyx
- Key ongoing clinical trials of Cabometyx in the treatment of renal cell carcinoma
- Expert insight: Cabometyx
- Key results from select clinical trials investigating Lenvima / Kisplyx for the treatment of renal cell carcinoma
- Ongoing clinical development of Lenvima / Kisplyx
- Expert insight: Lenvima / Kisplyx
- Key results from select clinical trials investigating Fotivda for the treatment of renal cell carcinoma
- Ongoing clinical development of Fotivda
- Key ongoing clinical trials of Fotivda in the treatment of renal cell carcinoma
- Expert insight: Fotivda
- Advantages and disadvantages of Torisel
- Expert insight: Torisel
- Ongoing clinical development of Afinitor
- Key ongoing clinical trials of Afinitor in the treatment of renal cell carcinoma
- Expert insight: Afinitor
- Key results from select clinical trials investigating Welireg for the treatment of renal cell carcinoma
- Ongoing clinical development of Welireg
- Key ongoing clinical trials of Welireg in the treatment of renal cell carcinoma
- Expert insight: Welireg
- Medical practice
- Early-stage renal cell carcinoma: stages I-III
- First-line advanced or metastatic renal cell carcinoma: stage IV
- Second- and subsequent-line advanced or metastatic renal cell carcinoma
- Patient characteristics influencing drug selection in renal cell carcinoma
- Treatment decision tree for renal cell carcinoma: United States
- Treatment decision tree for renal cell carcinoma: EU5
- Treatment decision tree for renal cell carcinoma: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in renal cell carcinoma
- Top unmet needs in renal cell carcinoma: current and future attainment
- Expert insight: unmet need in renal cell carcinoma
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for renal cell carcinoma
- Estimated market authorization dates of key emerging therapies for the treatment of renal cell carcinoma
- Analysis of clinical development program for Tecentriq
- Expert insight: Tecentriq
- Expectations for market authorization and sales opportunity of Tecentriq in renal cell carcinoma
- Key results from select clinical trials investigating tremelimumab and Imfinzi combination therapy for the treatment of renal cell carcinoma
- Analysis of the clinical development program for Imfinzi
- Key ongoing clinical trials of Imfinzi in the treatment of renal cell carcinoma
- Expert insight: Imfinzi
- Expectations for market authorization and sales opportunity of Imfinzi in renal cell carcinoma
- Key results from select clinical trials investigating tremelimumab and Imfinzi combination therapy for the treatment of renal cell carcinoma
- Analysis of clinical development program for tremelimumab and Imfinzi combination therapy
- Key ongoing clinical trials of tremelimumab and Imfinzi combination therapy in the treatment of renal cell carcinoma
- Expert insight: tremelimumab and Imfinzi combination therapy
- Expectations for market authorization and sales opportunity of tremelimumab and Imfinzi combination therapy in renal cell carcinoma
- Analysis of clinical development program for quavonlimab
- Key ongoing clinical trials of quavonlimab in the treatment of renal cell carcinoma
- Expert insight: quavonlimab
- Expectations for market authorization and sales opportunity of quavonlimab in renal cell carcinoma
- Key results from select clinical trials investigating Orpathys for the treatment of renal cell carcinoma
- Analysis of clinical development program for Orpathys
- Key ongoing clinical trials of Orpathys in the treatment of renal cell carcinoma
- Expert insight: Orpathys
- Expectations for market authorization and sales opportunity of Orpathys in renal cell carcinoma
- Key results from select clinical trials investigating zanzalintinib for the treatment of renal cell carcinoma
- Analysis of clinical development program for zanzalintinib
- Key ongoing clinical trials of zanzalintinib in the treatment of renal cell carcinoma
- Expectations for market authorization and sales opportunity of zanzalintinib in renal cell carcinoma
- Key results from select clinical trials investigating abexinostat for the treatment of renal cell carcinoma
- Analysis of clinical development program for abexinostat
- Key ongoing clinical trials of abexinostat in the treatment of renal cell carcinoma
- Expert insight: abexinostat
- Expectations for market authorization and sales opportunity of abexinostat in renal cell carcinoma
- Early-phase pipeline analysis
- Select compounds in early-phase development for renal cell carcinoma
- Key findings
- Access and reimbursement overview
- Region-specific reimbursement practices
- Key market considerations in renal cell carcinoma: United States
- General reimbursement environment: United States
- Key market access considerations in renal cell carcinoma: EU5
- General reimbursement environment: EU5
- Key market access considerations in renal cell carcinoma: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Renal cell carcinoma bibliography
- Key findings
Joan Tur, M.Sc., Ph.D., Healthcare Research & Data Analyst, Oncology. Dr. Tur conducts market research and forecasting in a range of oncology indications. He has several years of experience as a pharmaceutical industry analyst with the Cortellis Competitive Intelligence group, serving as the team’s immuno-oncology expert. Prior to joining Clarivate, Dr. Tur was a researcher in inflammation and macrophage biology at the Barcelona Science Park. He holds a Ph.D. in biomedicine, an M.Sc. in immunology, and a B.Sc. in biology from the University of Barcelona.
Kiran Bountra, M.Res., Ph.D., Senior Healthcare Research & Data Analyst, Oncology. Dr. Bountra has a background in the biotechnology sector, specializing in target validation and small-molecule drug discovery. Before joining Clarivate, he worked as a senior scientist at OMass Therapeutics, with a focus on basal cell carcinoma and epilepsy programs. Previously, he trained as a structural biologist, researching the mechanisms of transport proteins involved in drug resistance. He holds a Ph.D. in biochemistry from Imperial College London.